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Metabolic syndrome, a clustering of conditions including obesity,
insulin resistance, and hypertension, is a risk factor for cardiovas-
cular morbidity and mortality. Because peroxisome proliferator-
activated receptor  (PPAR) regulates adipocyte differentiation
and lipid metabolism and is the molecular target of a class of insulin
sensitizers, genetic variants that alter Pparg gene expression are
potential contributors to the metabolic syndrome. To test this
possibility, we generated mice having 182% of the normal steady-
state level of PPAR mRNA by replacing the 3-UTR of the natural
Pparg gene with that of the -globin gene, thereby stabilizing the
Pparg transcripts. This increase in PPAR mRNA level had no
apparent consequences in various physiological parameters, ex-
cept that the mice repeatedly showed a trend toward lower blood
pressures (by about 3 mm Hg) than their WT littermates. In
contrast, the opposite trend, toward increased blood pressure,
was observed in mice with genetically reduced levels of PPAR
mRNA as a consequence of insertion of an allele with an mRNA-
destabilizing sequence into the endogenous 3-UTR of the Pparg
gene. By combining 12 sets of blood pressure measurements in
more than 350 mutant mice having PPAR expression levels vary-
ing from 28% to 182% and more than 280 WT littermates, we show
that a 2-fold genetic increase (or decrease) in PPAR expression
levels decreases (or increases) blood pressure by about 2.8 mm Hg.
Thus, our experiments demonstrate that quantitative variants
causing decreased Pparg expression are a potential causative risk
factor for essential hypertension.
3-UTR  hypertension  metabolic syndrome  mouse models
Awareness is increasing that a significant number of adults inindustrialized countries develop a metabolic syndrome
characterized by a clustering of several abnormal traits, including
insulin resistance, dyslipidemia, essential hypertension, visceral
obesity, glucose intolerance, and noninsulin-dependent diabetes
mellitus (1). Although a familial tendency toward metabolic
syndrome suggests a genetic risk component, loci that predispose
individuals to this syndrome remain largely undefined. This is
partly because susceptibility to these conditions is likely deter-
mined by combinations of small changes in many genes. In
addition, although numerous genome-wide studies have been
carried out to identify single-nucleotide polymorphisms in the
human genome, determining whether an ‘‘association’’ identi-
fied by epidemiologic studies is ‘‘causative’’ remains a great
challenge. This problem is particularly evident with genetic
variations in noncoding sequences. Nevertheless, the problem of
determining whether quantitative genetic differences cause
complex changes can be resolved by the use of animal models,
as we report here for peroxisome proliferator–activated receptor
 (PPAR).
PPAR is a nuclear receptor that plays important roles in the
regulation of adipocyte differentiation and glucose homeostasis,
and also mediates the insulin-sensitizing effects of a class of
drugs, the thiazolidinediones (TZDs). Consequently, the gene
coding for PPAR (Pparg) is an excellent candidate for playing
a causative role in the development of metabolic syndrome.
Several human PPAR variants, spanning a wide spectrum of
activity, have been identified; however, the relationships be-
tween these inherited differences in PPAR activity and the
traits associated with the human metabolic syndrome remain
unclear. For example, the polymorphic P12A substitution, which
leads to a lower affinity for the peroxisome proliferator response
element and decreased transactivation in in vitro studies (2, 3),
is associated with lower body mass index and enhanced insulin
sensitivity in some, although not all, population studies (2, 4). In
contrast, 4 unrelated individuals carrying a P115Q substitution,
which increases PPAR activity by preventing S114 phosphor-
ylation, were severely obese and appeared to have greater-than-
expected insulin sensitivity (5). On the other hand, another
individual carrying the P115Q mutation was moderately over-
weight and had decreased insulin sensitivity (6). Other PPAR
mutations that result in production of transactivation-defective
proteins and decreased PPAR activity, such as P467L, V290M,
F360L, and R397C, are associated with lipodystrophy and severe
insulin resistance (7).
Extensive work exploring the influence of PPAR variations
on metabolism has been done using mouse models. A complete
lack of PPAR is embryonically lethal in homozygous knockout
mice (8, 9). Heterozygous PPAR-deficient mice are protected
from high-fat diet–induced weight gain and loss of insulin
sensitivity (9). Mice homozygous for a constitutively active form
of PPAR resulting from an S112A mutation (mouse S112 is
equivalent to human S114) gain weight normally and are pro-
tected against obesity-induced insulin resistance (10). Mice with
a mutation equivalent to the human P467L mutation maintain
normal insulin sensitivity with altered body fat distribution and
mild hypertension (11). The metabolic effects of simple increases
or decreases in PPAR expression level, such as can occur in
humans as a consequence of normal variations in noncoding or
regulatory regions of the gene, have not yet been explored.
In a previous study, we showed that the steady-state expression
of a gene can be modulated in vitro at the mRNA and protein
levels by changing its 3-UTR, with minimal effects on the
endogenous regulating machinery and no changes in the coding
sequence (12). In the present study, we used this approach to
study the in vivo effects of altering the steady-state expression
level of PPAR by changing the 3-UTR of the Pparg gene in
mice.
Results
Mice With Increased Pparg Expression. The targeting strategy used
to replace the WT mouse PPAR 3-UTR (the WT allele) with
the -globin 3-UTR (the B allele) is illustrated in Fig. 1A. The
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resulting modified Pparg-B allele retains all of the normal
PPAR regulatory elements in the promoter and coding sequences.
PpargB/ heterozygotes produced offspring in the expected
Mendelian proportions (Pparg/:PpargB/:PpargB/B 
68:127:48; P  .85 by the 2 test). Quantitative RT-PCR showed
that the steady-state PPAR message level in PpargB/B mice was
183% of that in WT littermates in adipose tissue, 149% in the
kidneys, 143% in the liver, and 128% in the heart (Fig. 1B). The
corresponding PPAR message levels in heterozygous PpargB/
mice were 128%, 129%, 121%, and 108%.
To confirm that the increased PPAR expression is due to
increased stability of the message, we measured the decay of the
PPAR transcripts from the Pparg-B allele relative to that from
the WT allele in the livers of PpargB/ heterozygotes after
injection of actinomycin D. Real-time RT-PCR using allele-
specific primers/probes showed that the PPAR transcripts from
the Pparg-B allele were more stable than those from the WT
allele (down to 70% after 2 h vs 50% after 2 h) (Fig. 1C, Left
Panel). This increased stability is in marked contrast to the
mRNA in the livers of PpargC/ heterozygotes, which have a
Pparg-C allele with a mRNA destabilizing sequence from the
c-fos gene inserted into its 3-UTR region (13); the unstable
transcript of Pparg-C allele was down to 30% after 2 h, whereas
mRNA from the WT allele was 55% (Fig. 1C, Right Panel).
Normal Metabolic Profiles in Mice with the Pparg-B Allele. The
homozygous PpargB/B mice developed normally and were
healthy. No abnormalities were found in the mutant mice
externally or internally on macroscopic examination. The growth
curves of both male and female PpargB/B mice were the same as
those of WT littermates fed regular chow. High-fat feeding
increased the body weight of all of the mice regardless of
genotype (Fig. 2A). Metabolic parameters from a set of PpargB/B
mice and their littermates are compared in Table S1. The organ
weights and total weights, as well as individual fat pad weights
[perigonadal, retroperitoneal, and inguinal white adipose tissue
(WAT) and interscapular brown adipose tissue] did not differ
significantly between the PpargB/B and WT mice, and the body
fat distribution was not altered in the PpargB/B mice (Fig. 2B).
Fasting plasma total cholesterol and free fatty acids also were not
altered in the PpargB/B mice (Table S1). In this set of littermates,
plasma levels of triglycerides were modestly but significantly
lower in the PpargB/B mice compared with the WT mice in both
females (30  1 mg/dL vs. 42  3 mg/dL) and males (35  1
mg/dL vs. 41  3 mg/dL) (P  .002 by ANOVA). However,
plasma levels of triglycerides were not significantly different in
the 3 other littermate groups (overall P  .7 by ANOVA, with
litter group, sex, and genotype as factors; n  45 for PpargB/B and
n  58 for Pparg/).
Plasma glucose and insulin concentrations were normal in
PpargB/B mice in the fasted state. However, these mice exhibited
slower glucose clearance than their WT littermates following a
glucose load (Fig. 3A), as well as significantly higher plasma
glucose levels 120 min after a glucose load (279  38 mg/dL vs.
190  17 mg/dL; P  .05). Insulin levels during glucose tolerance
Fig. 1. Mice with increased PPAR gene expression. (A) Gene-targeting
strategy. The WT mouse Pparg locus has a 345-bp 3-UTR (gray box) in exon 6.
The targeting construct contains an 855-bp -globin 3-UTR (black box), ACN
(testis-specific Ace promoter–driven Cre and pMC1Neo) cassette flanked by
loxP sequences (white triangles), thymidine kinase (TK), and a plasmid vector
sequence (dotted line). Homologous recombination in ES cells results in the
targeted allele having a 6.9-kb BamHI fragment instead of an 11.0-kb endog-
enous fragment that hybridized to a probe from the exon 6 coding region. The
ACN cassette is excised on germline transmission, and subsequent PpargB/
offspring carry a mutant allele. B, X, Xb, and St indicate BamHI, XhoI, XbaI, and
StuI restriction enzyme sites, respectively. (B) PPAR mRNA levels in PpargB/
(n  7) and PpargB/B (n  9) tissues relative to those of Pparg/ (n  10) tissues.
*, P  .05; **, P  .01 against Pparg/ littermates. (C) PPAR mRNA stability.
Hepatic mRNA was isolated from heterozygous PpargB/ mice (Left Panel) or
PpargC/ mice (Right Panel) before and 2 h after a tail vein injection of
actinomycin D and -amanitin. Between 6 and 8 mice were used for each time
point. The levels of PPAR mRNA were determined by allele-specific RT-PCR
and are expressed relative to the levels at the zero time point. *, P  .05; **,
P  .001 between 2 two alleles. Wt, WT allele; B, Pparg-B allele; C, Ppar-C allele.
Fig. 2. Body weights and body fat distribution. (A) Body weight increases in
females (Left Panel: Pparg/, n  7; PpargB/B, n  5) and males (Right Panel:
Pparg/, n  10; PpargB/B, n  7) fed a high-fat diet. No statistical differences
were noted at any time point. (B) Adipose tissue mass in 14-week-old male
Pparg/ (n  10) and PpargB/B (n  9) mice fed regular chow, expressed as
percentage of body weight. Per, Ret, and Ing represent perigonadal, retro-
peritoneal, and inguinal WAT, respectively; BAT indicates interscapular brown
adipose tissue; P/I indicates the ratio of perigonadal fat weight to inguinal fat
weight.











testing were not significantly different in the 2 genotypes. Insulin
tolerance tests showed similar glucose-lowering effects of insulin
in the 2 genotypes (Fig. 3B). Thus, the PpargB/B mice appeared
to have normal insulin sensitivity but possibly slightly impaired
postprandial glucose tolerance.
We next examined the effect of a high-fat diet on the insulin
sensitivity of these animals. Glucose clearance and insulin
secretion following a glucose load were similar in the PpargB/B
mice and their WT littermates fed a high-fat diet for 3 months
(Fig. 3C). The PpargB/B mice showed a decreased hypoglycemic
effect in response to exogenous insulin compared with their WT
littermates, although the differences in plasma glucose level at
specific time points were not significant (Fig. 3D). Taken to-
gether, these results indicate that an increase in the expression
of the Pparg gene to 182% of normal has only a minor impact on
glucose metabolism, but could lead to a decrease in insulin
sensitivity when combined with a high-fat diet.
PPAR Gene Expression and Blood Pressure. Blood pressure assessed
in conscious mice by tail-cuff measurement showed that both
4-month-old male and female PpargB/B mice had lower blood
pressure (by 3 mm Hg) than their WT littermates (genotype
effect, P  .09 by ANOVA; Table 1). Pulse rates did not differ
in these 2 genotypes in either males or females. Blood pressures
were also lower in PpargB/B mice fed a high-fat diet for 4 months
compared with their WT littermates (genotype effects, P  .01
and .06 by ANOVA, respectively; Table 1). Although the dif-
ferences in average blood pressure of the PpargB/B and Pparg/
mice in the 6 groups of animals from the 3 experiments did not
reach statistical significance, it is noteworthy that the PpargB/B
mice had lower blood pressures than their WT littermates in all
6 groups of animals that differed by diet, age, and gender.
This trend toward reduced blood pressures in mice with 182%
of normal PPAR expression encouraged us to examine the
blood pressure effects of PPAR gene expression levels over a
wider range. Seven genotypes of mice were used; their PPAR
expression levels relative to WT mice (100%) in WAT, in
ascending order, were PpargC/, 28%; PpargC/C, 52%; Pparg/,
60%; PpargC/, 77%; Pparg/, 100%; PpargB/, 128%; and
PpargB/B, 182% (Fig. 4A). We observed a trend toward higher
blood pressures in mice with reduced PPAR gene expression;
blood pressure was higher in the PpargC/ mice than in their
Pparg/ littermates in 5 of 6 sets, analyzing males females
separately, and the differences were significant in 2 sets
(Table S2C).
Fig. 3. Normal glucose tolerance and insulin sensitivity in PpargB/B mice. (A) Plasma glucose (Left Panel) and insulin levels (Right Panel) during glucose tolerance
tests on male mice fed regular chow (1416 weeks old; n  8–10). (B) Insulin tolerance tests on female mice fed regular chow (1416 weeks old; n  7–12). Data
are expressed as percentage of plasma glucose level before insulin injection. (C) Glucose tolerance tests on males fed a high-fat diet for 3 months (2022 weeks
old; n  14–19). Plasma levels of glucose (Right Panel) and insulin (Left Panel) are shown. (D) Insulin tolerance tests on females on a high-fat diet for 3 months
(2022 weeks old; n  12–16). *, P  .05 against Pparg/ littermates.
Table 1. Tail-cuff blood pressure measurements in PpargB/B (B/B) and Pparg/ (/) mice
Experiment
Females Males
PB/B / B/B /
Blood pressure, mm Hg
[a] 4 months, RC 100  2 (13) 103  2 (18) 97  2 (15) 100  2 (18) .09
[b] 8 months, HF 100  2 (13) 103  2 (19) 94  3 (13) 100  1 (18) .01
[c] 6 months, HF 94  2 (10) 96  2 (15) 93  1 (10) 98  4 (6) .06
Pulse rate, beats/min
[a] 4 months, RC 734  8 (13) 735  7 (17) 724  16 (13) 716  14 (18) .70
[b] 8 months, HF 720  9 (13) 740  8 (18) 699  8 (12) 719  7 (18) .02
[c] 6 months, HF 680  11 (10) 688  8 (15) 653  9 (10) 640  15 (6) .80
RC, regular chow; HF, Western-style high-fat diet. Data are mean  SEM. The numbers of mice are given in parentheses.
[a], [b], and [c] indicate experiment numbers. P values show genotype effects by ANOVA, with gender and genotype as 2
factors.
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In 12 experiments, designated [a]–[l], carried out over a 3-year
period, blood pressures were measured in a total of 356 mutants
and their 285 WT littermates (Tables 1 and S2). Each experiment
involved litters matched with respect to age, diet, and genetic
background. Because these factors differed between the 12
experiments, but not within each experiment, we analyzed the
effects of PPAR expression on blood pressure treating the
experiment as a random effect. The analysis showed that blood
pressure was significantly influenced by the mean level of
PPAR mRNA in mice of the 7 PPAR genotypes studied (P 
.0012; parameter estimate of 2.79  0.86 mm Hg per 2-fold
difference in expression; Table S3). This relationship is illus-
trated in Fig. 4B, in which the difference in blood pressure of
individual animals from the mean blood pressure of the WT
littermates within each experiment was used to derive an average
blood pressure difference from normal for each genotype group.
This difference was then plotted against the average fold change
in PPAR mRNA level for mice of the corresponding genotype.
The combined data clearly indicate an inverse relationship
between PPAR expression level and blood pressure, with a
2-fold change in the level of PPAR mRNA altering blood
pressure by about 2.8 mm Hg.
Discussion
Taking advantage of the mRNA stabilizing/destabilizing features
of the 3-UTR sequence, we created a Pparg-B allele that confers
an inherited increase in the level of PPAR gene expression in
mice without directly affecting the transcriptional regulation of
the gene. Transcripts from the Pparg-B allele retain the original
PPAR coding sequences but also have a 3-UTR from a
-globin gene. Our expectation that the steady-state expression
level of the PPAR gene would increase in mice carrying the
Pparg-B allele was confirmed by the level of PPAR message,
which in PpargB/B homozygotes was 182% of that in WT litter-
mates. Remarkably, this expression change occurred not only in
adipose tissues, where PPAR expression is high, but also in the
liver and kidney, where PPAR expression is much lower. The
availability of the Pparg-B allele, together with the Pparg-C allele
(which has mRNA- destabilizing elements of the c-fos gene
inserted into the endogenous Pparg 3-UTR), allowed us to
genetically vary PPAR expression between 28% and 182%.
The half-life of PPAR mRNA in a tissue culture system has
been reported to be 2.8 h (14), which is similar to our
observation of 2 h in vivo in the liver. Some 3-UTR sequences,
such as that of -globin mRNA (half-life 17 h), are known to
have message-stabilizing properties (15), while other 3-UTR
sequences, such as that in c-fos mRNA (half-life 0.3 h), lead to
very unstable mRNA (16). In our study, the half-life of the
PPAR message was approximately doubled in the Pparg-B
allele and approximately halved in the Pparg-C allele. Thus, the
observed alteration in the steady-state levels of the PPAR
message in mice carrying these Pparg alleles is a direct conse-
quence of changes in mRNA stability in vivo. We note that the
range of variations in the steady-state level of PPAR mRNA
(52%–182% of normal) resulting from the 3-UTR modifica-
tions is significantly smaller than that expected from tests with
a reporter gene expression system in cultured cells using the
same 3-UTR sequences (10%–350% of normal) (12). But in the
reporter expression system, the GFP gene with a test 3-UTR
sequence is inserted into the Hprt locus and is driven by a
constitutive -actin promoter, and consequently lacks the en-
dogenous feedback regulation and chromosomal context of the
native gene. Furthermore, factors that affect message stability
likely differ between tissues in vivo and embryonic stem cells in
culture. Moreover, we cannot exclude the possibility that the
altered 3-UTR sequences in the endogenous Pparg gene, in
addition to their posttranscriptional effects, might have affected
chromatin remodeling and transcription levels. Nevertheless, the
changes in the Pparg gene expression observed in our mutant
animals are within the physiological range that might occur in
humans.
While activation of PPAR by TZD in both humans and mice
clearly increases insulin sensitivity and increases body and fat
weights (17), the nearly double PPAR message seen in the
homozygous PpargB/B mice did not affect their body or total fat
weights. In addition, the PpargB/B mice had normal insulin
sensitivity. The absence of any significant effect on these vari-
ables of doubling PPAR mRNA levels could be due to the
existence of posttranscriptional compensation, although protein
synthesis usually increases or decreases roughly in proportion to
the amount of RNA transcripts. Alternatively, moderate over-
expression of PPAR by itself may not be sufficient to change the
phenotypic outcome. This possibility also is suggested by studies
in cultured cells showing that overexpression of WT PPAR has
only a weak adipogenic effect in the absence of ligands (18, 19).
Despite these various caveats, our results demonstrate that
modestly increased PPAR mRNA levels lower basal blood
pressure. The effect is small, and a large number of experimental
animals with both higher-than-normal and lower-than-normal
Pparg expression were needed to reach this conclusion. None-
theless, we stress that each set of blood pressure measurements
was carried out with littermates (mutant and WT), which
allowed us to estimate that a 2-fold genetic increase (or decrease)
in PPAR expression decreases (or increases) blood pressure by
about 2.8 mm Hg. Most of our current knowledge concerning the
blood pressure–decreasing effects of increased PPAR activity
Fig. 4. Effects of increased/decreased PPAR gene expression on blood
pressure. (A) Average PPAR mRNA levels in WATs of PpargC/ (C/), PpargC/C
(C/C), Pparg/ (/), PpargC/ (C/), PpargB/ (B/), and PpargB/B (B/B) mice
relative to their Pparg/ littermates (/, 100%). *, P  .05; **, P  .01; ***,
P  .001 against Pparg/ mice. There were 7–9 mice in each group. (B) Mean 
SEM of the blood pressure differences in individual mice from the mean blood
pressure of Pparg/ littermates within each experiment. n  49, 40, 38, 115,
285, 51, and 73 for C/, C/C, /, C/, /, B/ and B/B mice, respectively. The
x-axis is the fold change in the average level of PPAR gene expression in each
genotype group from that of their WT littermates determined in (A). The black
line indicates a slope of 2.8 mm Hg per 2-fold difference in the expression of
PPAR. The correlation between the mean blood pressure difference for each
genotype and the mean expression level for each genotype was r  0.92 (P 
.005; n  7).











is based on the effect of TZDs (17). This relationship was first
observed in patients with type 2 diabetes and was found to be
independent of changes in insulin sensitivity. TZDs also have
been found to attenuate the blood pressure increase resulting
from angiotensin II infusion in rats (20) and to improve vascular
function in normoglycemic mice with hypertension (21). Data on
the effects of decreasing PPAR activity are available as well.
Thus, humans with the dominant-negative P467L mutation are
hypertensive, and we have previously shown that an equivalent
PPAR-P465L mutation in mice causes a 7 mm Hg increase in
blood pressure (11). Transgenic mice that overexpress the
human PPAR gene with a P467L mutation in vascular smooth
muscle cells also have elevated blood pressure (22). Our dem-
onstration of an inverse relationship between genetically deter-
mined levels of PPAR expression and blood pressure is con-
sistent with these observations.
The increased blood pressure in our mice with decreased
Pparg expression differs from the hypotensive phenotype
described in mice with a generalized lack of PPAR (23). A
complete absence of PPAR causes embryonic death, but the
investigators in that previous study were able to rescue them
from lethality by using a Cre-loxP system that deletes the Pparg
gene in the epiblast (and so also in the embryos), but not in
extraembryonic tissues. The rescued PPAR-null mice, des-
ignated MORE-PGKO, were severely lipodystrophic and
insulin-resistant, but had decreased blood pressure as mea-
sured by telemetric recording in a limited number of mice. In
contrast, the mutants generated in our experiment had no
overt metabolic phenotype, except that the PpargC/ mice with
28% normal expression had 30% less fat mass and were
mildly insulin-resistant (24), and in our study blood pressure
measurement was done using the tail-cuff method in a large
number of mice. The different outcomes of the 2 experiments
could be related to the difference between the effects of a
modest quantitative reduction in the expression of a protein
compared with the effects of the complete absence of that
protein. Further studies are needed to elucidate the precise
mechanisms through which PPAR expression regulates blood
pressure.
The changes in the PPAR expression levels in the series of
Pparg mutants that we have generated and studied are within a
physiological range that may occur in humans as a consequence
of polymorphic variations. Moreover, these mice had no changes
in the genome other than in the Pparg 3-UTR sequence, and
they produced normal PPAR protein in all relevant tissues.
Consequently, these mice are valuable predictors of the effects
of quantitative genetic variations in human individuals. The clear
inverse relationship between basal expression levels of PPAR
and blood pressure revealed in our experiments in mice suggests
that variations in the Pparg locus could play a causative role in
determining basal blood pressures in humans. Thus, although the
2- to 3-mm Hg change in the basal blood pressure that we
observed when PPAR expression was doubled or halved is not
large, it is comparable to that seen in other human polymor-
phisms. For example, the M235T polymorphism in the angio-
tensinogen gene in humans is in linkage disequilibrium with a
promoter variant A-6T that causes a 2-fold difference in expres-
sion level (25). A recent meta-analysis involving 26,818 subjects
from 46 studies reported a small but significant association of the
235T allele with hypertension, with an odds ratio of 1.2 (26).
In a large, homogeneous study population, Ortlepp et al. (27)
estimated that the M235T polymorphism explains about 2 mm
Hg of the difference in diastolic blood pressure. The difficulty in
establishing the existence of such small effects may be partly
responsible for the lack of agreement between published studies
of genetic associations between Pparg polymorphisms and hy-
pertension in humans (28–30). Our study of mice with varying
Pparg expression created by modifying its 3-UTR sequence
indicates that quantitative variants causing decreased Pparg
expression are a potential causative risk factor for essential
hypertension.
Materials and Methods
Targeting Construct Design. A mouse genomic DNA (129/SvEv strain) contain-
ing PPAR exon 6 and 3-UTR was cloned from a  phage library, and 5.5-kb
and 9.4-kb XhoI fragments were subcloned into pBlueScript. To generate mice
with increased steady-state levels of PPAR mRNA, a 345-bp BglII/NdeI frag-
ment containing the PPAR 3-UTR was replaced with an 855-bp rabbit
-globin 3-UTR (Fig. 1A). The fragment was cloned into the targeting vector,
which contains a 6.5-kb XhoI/XbaI 5-homology fragment, the ACN (testis-
specific ACE promoter, Cre recombinase, and neomycin- resistance gene)
cassette (31), a 1.3-kb XbaI/StuI 3-homology fragment, and a thymidine
kinase gene.
Generation of PPAR Mutant Mice. Electroporation of linearized vector into
TC-1 ES cells of 129S6 origin and selection with G418 and ganciclovir were
performed as described previously (32). Successful modifications of the Pparg
locus were identified by PCR and confirmed by Southern blot analysis, which
showed the presence of a 6.9-kb BamHI restriction fragment expected for the
Pparg-B allele when hybridized with a probe derived from the exon 6 se-
quence. Targeted ES cell clones were injected into C57BL/6 blastocysts and
transferred into pseudopregnant females to obtain chimeric offspring. The
ACN cassette, flanked by loxP sequences, was excised out in mice on germline
transmission. Male chimeras transmitted the mutant PPAR alleles, and the
lines were maintained on 129S6 genetic background. The Pparg-B allele was
placed onto C57BL/6J by backcrossing for 4–5 generations before intercross-
ing to generate Pparg/, PpargB/, and PpargB/B littermates for subsequent
studies. The production of mice carrying the Pparg-C allele with an mRNA-
destabilizing sequence from the c-Fos gene inserted into its 3-UTR region was
described previously (13, 24). The mice were housed in a pathogen-free barrier
facility (12 h/12 h light/dark cycle) and fed ad libitum either a regular chow diet
(LabDiet 5P76; PMI Nutrition International) or a high-fat diet (D12451; Re-
search Diets) consisting of 45% calories as fat, 35% as carbohydrate, and 20%
as protein. All animal studies were approved by the Institutional Animal Care
and Use Committees of the University of North Carolina-Chapel Hill and the
National Cheng Kung University.
Tissue Collection and RNA Analysis. Mice were euthanized with an overdose of
2,2,2,-tribromoethanol, and tissues were collected and stored in RNAlater
(Ambion). Tissue RNA was extracted using the RNAeasy Kit (Qiagen), and
mRNA was analyzed by real-time quantitative RT-PCR using an ABI Prism 7700
(Applied Biosystems), with -actin or Gapdh as the reference gene in each
reaction. To assay RNA degradation, heterozygous mice were injected with
actinomycin D (1.5 g/g body weight; Calbiochem) and -amanitin (0.5 g/g
body weight; Sigma) through the tail vein. Liver mRNA was isolated before
and 2 h after injection, and the message level for each allele was analyzed
using allele-specific oligo primers.
Lipid Metabolism. Plasma total cholesterol (Cholesterol E; Wako Chemicals),
free fatty acid (NEFA C; Wako Chemicals), and triglyceride (Stanbio Labora-
tory) were measured using standard colorimetric tests.
Glucose and Insulin Tolerance Tests. Mice were fasted for 5 h and injected i.p.
with glucose (1 g/kg body weight) or human regular insulin (0.5 or 0.75 U/kg
body weight; Humulin; Eli Lilly). Blood samples were collected before and at
indicated times after injections. Plasma glucose concentration was deter-
mined by a glucose colorimetric test (Autokit Glucose; Wako Chemicals).
Insulin concentration was measured with rat insulin ELISA (Crystal Chemical).
Tail-Cuff Blood Pressure Measurements. Blood pressure and pulse rate were
measured noninvasively in conscious, restrained mice by the tail-cuff method
(33). The blood pressure of an individual animal was represented by the mean
of the daily averages of 30 trials per day for 6 consecutive days. Each set of
experiments included an average of 12 (at least 5) mice of each genotype and
gender group and similar numbers of WT littermates. Experimental sets
differed by age, diet, and genetic background of the mice. Blood pressures of
PpargB/ and PpargB/B littermates were from intercrosses of the fifth-
generation backcross toward C57BL/6J, and those of PpargC/C and PpargC/
mice were measured in F2 littermates between 129S6 and C57BL/6J. PpargC/
and Pparg/ mice were F1 between PpargC/ heterozygotes (at the seventh
19088  www.pnas.orgcgidoi10.1073pnas.0909657106 Tsai et al.
generation backcrossed to C57BL/6J) and Pparg/ heterozygotes on 129S6
background (8), provided by Dr. Ronald Evans (Salk Institute).
Data Analysis. Values are reported as mean  SEM. Statistical analysis was
conducted with 2-way ANOVA, using genotype and gender as factors. The
Student t test was used for comparisons between mutant and WT mice within
each group, and differences were considered statistically significant at P  .05.
To estimate the effect of PPAR expression on blood pressure, the mean mRNA
level in the WAT of mice in each genotype determined in a separate set of
animals was treated as continuous variable, using an ANCOVA model, treating
the experiment as a random effect. The animals’ age, sex, and diet were
included in the model as fixed effects.
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